Base de dados : MEDLINE
Pesquisa : D03.383.773.812.718 [Categoria DeCS]
Referências encontradas : 2693 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 270 ir para página                         

  1 / 2693 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29395088
[Au] Autor:Loganathan K; Moriya S; Parhar IS
[Ad] Endereço:Brain Research Institute, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor, 47500, Malaysia.
[Ti] Título:Trek2a regulates gnrh3 expression under control of melatonin receptor Mt1 and α -adrenoceptor.
[So] Source:Biochem Biophys Res Commun;496(3):927-933, 2018 02 12.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Gonadotrophin-releasing hormone (GnRH) expression is associated with the two-pore domain potassium ion (K ) channel-related K (TREK) channel trek2a expression and melatonin levels. We aimed to investigate correlation of trek2a expression with gnrh3 expression, and regulatory mechanisms of trek2a expression by the melatonin receptor Mt1 and α -adrenoceptor which are regulated by melatonin. trek2a specific siRNA, Mt1 antagonist luzindole and α -adrenoceptor antagonist prazosin were administered into the adult zebrafish brain and gene expressions were examined by real-time PCR. trek2a specific siRNA administration significantly reduced expression levels of trek2a, gnrh3 and mt1. Luzindole administration suppressed trek2a and gnrh3 expressions. Prazosin administration reduced trek2a and gnrh3 expressions. It is suggested that Trek2a regulates gnrh3 expression under the control of Mt1 and α -adrenoceptor.
[Mh] Termos MeSH primário: Encéfalo/metabolismo
Hormônio Liberador de Gonadotropina/metabolismo
Melatonina/metabolismo
Canais de Potássio de Domínios Poros em Tandem/metabolismo
Ácido Pirrolidonocarboxílico/análogos & derivados
Receptor MT1 de Melatonina/metabolismo
Receptores Adrenérgicos alfa 2/metabolismo
Proteínas de Peixe-Zebra/metabolismo
[Mh] Termos MeSH secundário: Animais
Células Cultivadas
Regulação da Expressão Gênica/fisiologia
Masculino
Ácido Pirrolidonocarboxílico/metabolismo
Transdução de Sinais/fisiologia
Peixe-Zebra
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (K(2P)10.1 protein, zebrafish); 0 (Potassium Channels, Tandem Pore Domain); 0 (Receptor, Melatonin, MT1); 0 (Receptors, Adrenergic, alpha-2); 0 (Zebrafish Proteins); 0 (gonadotropin-releasing hormone-III); 33515-09-2 (Gonadotropin-Releasing Hormone); JL5DK93RCL (Melatonin); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180204
[St] Status:MEDLINE


  2 / 2693 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29227608
[Au] Autor:Golovenko NY; Larionov VB; Karpova OV
[Ti] Título:Physical-chemical properties and the reactivity of pyridoxine and pyrrolidone carboxylate and their protolytic forms.
[So] Source:Ukr Biochem J;88(2):73-81, 2016 Mar-Apr.
[Is] ISSN:2409-4943
[Cp] País de publicação:Ukraine
[La] Idioma:eng
[Ab] Resumo:Preparation Methadoxine is equimolar salt, which cationic component (pyridoxine) is 3-oxypyridine derivative, possessing B6-vitamine like activity, while anionic component is the cyclic lactame of glutamic acid. Since biopharmaceutical and pharmacological properties of this drug depend on biochemical transformation its components, of the aim of this work was to determine the structure of possible ionized pyridoxine and pyrrolidone carboxylate forms and their reaction ability in biochemical processes. Physical-chemical properties of compounds (pKa, logP, logD, proton donor/acceptor quantity, solubility (g/l)) were calculated with ACD/pKaDB program or obtained from Pub-Med physical/chemical properties database. UV spectra of compounds were obtained after dissolution in different pH solutions (1.0, 4.5 and 6.8). It was found that at different pH values one can observe changes of the absorption spectra due to the presence of prevailing amount of the protonated form. An analysis of both pKa, logP and logD indicators and reactive functional groups of Methadoxine components has revealed that they can be protonated in different regions of gastro-intestinal tract, that influences their solubility in hydrophilic and lypophilic media. Pharmacological properties of pyridoxine and pyrrolidone carboxylate themselves are performed after their preliminary biotransformation to active metabolites. Only ionic interaction between Methadoxine components in the substance composition can appear, that provides its pharmaceutical stability and ensures its activity only in the organism conditions.
[Mh] Termos MeSH primário: Ácido Glutâmico/química
Lactamas Macrocíclicas/química
Prótons
Piridoxina/química
Ácido Pirrolidonocarboxílico/química
[Mh] Termos MeSH secundário: Estabilidade de Medicamentos
Concentração de Íons de Hidrogênio
Interações Hidrofóbicas e Hidrofílicas
Solubilidade
Soluções
Espectrofotometria Ultravioleta
Água/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Lactams, Macrocyclic); 0 (Protons); 0 (Solutions); 059QF0KO0R (Water); 3KX376GY7L (Glutamic Acid); KV2JZ1BI6Z (Pyridoxine); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.15407/ubj88.02.073


  3 / 2693 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28830929
[Au] Autor:Niehaus TD; Elbadawi-Sidhu M; de Crécy-Lagard V; Fiehn O; Hanson AD
[Ad] Endereço:From the Horticultural Sciences Department, University of Florida, Gainesville, Florida 32611, tomniehaus@ufl.edu.
[Ti] Título:Discovery of a widespread prokaryotic 5-oxoprolinase that was hiding in plain sight.
[So] Source:J Biol Chem;292(39):16360-16367, 2017 Sep 29.
[Is] ISSN:1083-351X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:5-Oxoproline (OP) is well-known as an enzymatic intermediate in the eukaryotic γ-glutamyl cycle, but it is also an unavoidable damage product formed spontaneously from glutamine and other sources. Eukaryotes metabolize OP via an ATP-dependent 5-oxoprolinase; most prokaryotes lack homologs of this enzyme (and the γ-glutamyl cycle) but are predicted to have some way to dispose of OP if its spontaneous formation is significant. Comparative analysis of prokaryotic genomes showed that the gene encoding pyroglutamyl peptidase, which removes N-terminal OP residues, clusters in diverse genomes with genes specifying homologs of a fungal lactamase (renamed rokaryotic 5-o oprolinase , ) and homologs of allophanate hydrolase subunits (renamed and ). Inactivation of , , or genes slowed growth, caused OP accumulation in cells and medium, and prevented use of OP as a nitrogen source. Assays of cell lysates showed that ATP-dependent 5-oxoprolinase activity disappeared when , , or was inactivated. 5-Oxoprolinase activity could be reconstituted by mixing recombinant PxpA, PxpB, and PxpC proteins. In addition, overexpressing genes in increased 5-oxoprolinase activity in lysates ≥1700-fold. This work shows that OP is a major universal metabolite damage product and that OP disposal systems are common in all domains of life. Furthermore, it illustrates how easily metabolite damage and damage-control systems can be overlooked, even for central metabolites in model organisms.
[Mh] Termos MeSH primário: Alofanato Hidrolase/metabolismo
Amidoidrolases/isolamento & purificação
Bacillus subtilis/enzimologia
Proteínas de Bactérias/metabolismo
[Mh] Termos MeSH secundário: Alofanato Hidrolase/genética
Amidoidrolases/genética
Amidoidrolases/metabolismo
Proteínas de Bactérias/genética
Escherichia coli/enzimologia
Proteínas de Escherichia coli/genética
Proteínas de Escherichia coli/metabolismo
Deleção de Genes
Técnicas de Inativação de Genes
Genômica/métodos
Família Multigênica
Mutação
Subunidades Proteicas/genética
Subunidades Proteicas/metabolismo
Ácido Pirrolidonocarboxílico/metabolismo
Proteínas Recombinantes/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Escherichia coli Proteins); 0 (Protein Subunits); 0 (Recombinant Proteins); EC 3.5.- (Amidohydrolases); EC 3.5.1.54 (Allophanate Hydrolase); EC 3.5.2.9 (5-oxoprolinase (ATP-hydrolyzing)); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1074/jbc.M117.805028


  4 / 2693 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28684460
[Au] Autor:Yuan PQ; Taché Y
[Ad] Endereço:CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress and Resilience, Vatche and Tamar Manoukian Digestive Diseases Division, Department of Medicine and Brain Research Institute, University of California, Los Angeles, California; and pqyuan@mednet.ucla.edu.
[Ti] Título:Abdominal surgery induced gastric ileus and activation of M1-like macrophages in the gastric myenteric plexus: prevention by central vagal activation in rats.
[So] Source:Am J Physiol Gastrointest Liver Physiol;313(4):G320-G329, 2017 Oct 01.
[Is] ISSN:1522-1547
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Inflammation plays a role in abdominal surgery (AS)-induced intestinal ileus that is alleviated by electrical vagal stimulation. Intracisternal injection of RX-77368, the stable thyrotropin-releasing hormone agonist, activates dorsal motor nucleus neurons and gastric vagal efferent discharges. We investigated the gastric inflammation induced by AS and the modulation by intracisternal RX-77368 in rats. RX-77368 (50 ng/rat) or saline was injected followed, 1 h later, by laparotomy and small intestinal/cecal manipulation. The sham group had anesthesia alone. After 6 h, gastric emptying (GE) and the inflammation in gastric corpus were determined. AS inhibited GE by 72% vs. control and doubled the number of M1-like macrophage immunoreactive for major histocompatibility complex class II (MHCII; M1 marker) but not for cluster of differentiation 206 (CD206; M2 marker) (MHCII /CD206 ) while there was no change in M2-like macrophages (MHCII /CD206 ). AS increased mRNA levels of interleukin-1ß (IL-1ß) and tumor necrosis factor α (TNF-α) by 1.7- and 1.5-fold, respectively, in the gastric submucosa plus muscle layers and the infiltration of neutrophils labeled by myeloperoxidase by 9.5-fold in the muscularis externa. RX-77368 inhibited AS-related gastric changes while not altering these parameters in the sham group. There was a significant negative correlation between GE and IL-1ß ( = -0.46), TNF-α ( = -0.44), M1 macrophage ( = -0.82), and neutrophils ( = -0.91). The M2-like macrophages and IL-10 expression were unchanged by AS with intracisternal saline or RX-77368. These data indicate that AS activates gastric M1 macrophages and increases proinflammatory cytokines expression, which are prevented by central vagal activation and may contribute to the correlated dampening of postoperative gastric ileus. MHCII /CD206 (M1) and MHCII /CD206 (M2) constitute two distinct populations of macrophages that are in close apposition to the cholinergic neurons in the rat gastric myenteric plexus (MP). Abdominal surgery (6 h) activates M1 macrophage leading to inflammation in the gastric MP correlated with the delayed gastric emptying, which was abolished by central vagal stimulation via intracisternal injection of RX-77368. Vagal stimulation linked with the cephalic phase may have potential beneficial effects to curtail postoperative gastric ileus.
[Mh] Termos MeSH primário: Enterostomia/efeitos adversos
Motilidade Gastrointestinal/imunologia
Pseudo-Obstrução Intestinal/imunologia
Pseudo-Obstrução Intestinal/prevenção & controle
Ativação de Macrófagos/imunologia
Plexo Mientérico/fisiopatologia
Nervo Vago/fisiopatologia
[Mh] Termos MeSH secundário: Animais
Motilidade Gastrointestinal/efeitos dos fármacos
Pseudo-Obstrução Intestinal/etiologia
Ativação de Macrófagos/efeitos dos fármacos
Masculino
Plexo Mientérico/efeitos dos fármacos
Complexo Mioelétrico Migratório/efeitos dos fármacos
Complexo Mioelétrico Migratório/imunologia
Ácido Pirrolidonocarboxílico/administração & dosagem
Ácido Pirrolidonocarboxílico/análogos & derivados
Ratos
Ratos Sprague-Dawley
Hormônio Liberador de Tireotropina/administração & dosagem
Hormônio Liberador de Tireotropina/análogos & derivados
Resultado do Tratamento
Nervo Vago/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
5Y5F15120W (Thyrotropin-Releasing Hormone); 76820-40-1 (L-pyroglutamyl-L-histidyl-3,3-dimethylprolinamide); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE
[do] DOI:10.1152/ajpgi.00121.2017


  5 / 2693 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28623233
[Au] Autor:Piechotta A; Parthier C; Kleinschmidt M; Gnoth K; Pillot T; Lues I; Demuth HU; Schilling S; Rahfeld JU; Stubbs MT
[Ad] Endereço:From Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany.
[Ti] Título:Structural and functional analyses of pyroglutamate-amyloid-ß-specific antibodies as a basis for Alzheimer immunotherapy.
[So] Source:J Biol Chem;292(30):12713-12724, 2017 Jul 28.
[Is] ISSN:1083-351X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Alzheimer disease is associated with deposition of the amyloidogenic peptide Aß in the brain. Passive immunization using Aß-specific antibodies has been demonstrated to reduce amyloid deposition both and Because N-terminally truncated pyroglutamate (pE)-modified Aß species (Aß ) exhibit enhanced aggregation potential and propensity to form toxic oligomers, they represent particularly attractive targets for antibody therapy. Here we present three separate monoclonal antibodies that specifically recognize Aß with affinities of 1-10 nm and inhibit Aß fibril formation application of one of these resulted in improved memory in Aß oligomer-treated mice. Crystal structures of F -Aß complexes revealed two distinct binding modes for the peptide. Juxtaposition of pyroglutamate pE3 and the F4 side chain (the "pEF head") confers a pronounced bulky hydrophobic nature to the Aß N terminus that might explain the enhanced aggregation properties of the modified peptide. The deep burial of the pEF head by two of the antibodies explains their high target specificity and low cross-reactivity, making them promising candidates for the development of clinical antibodies.
[Mh] Termos MeSH primário: Doença de Alzheimer/imunologia
Doença de Alzheimer/terapia
Peptídeos beta-Amiloides/imunologia
Anticorpos Monoclonais/química
Anticorpos Monoclonais/imunologia
Imunoterapia
Ácido Pirrolidonocarboxílico/imunologia
[Mh] Termos MeSH secundário: Peptídeos beta-Amiloides/química
Animais
Células Cultivadas
Camundongos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amyloid beta-Peptides); 0 (Antibodies, Monoclonal); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170618
[St] Status:MEDLINE
[do] DOI:10.1074/jbc.M117.777839


  6 / 2693 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28620971
[Au] Autor:Gäde G; Marco HG
[Ad] Endereço:Department of Biological Sciences, University of Cape Town, Rondebosch, South Africa.
[Ti] Título:The adipokinetic hormone of the coleopteran suborder Adephaga: Structure, function, and comparison of distribution in other insects.
[So] Source:Arch Insect Biochem Physiol;95(3), 2017 Jul.
[Is] ISSN:1520-6327
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of the current study is to identify the adipokinetic hormone(s) (AKHs) of a basal suborder of the species-rich Coleoptera, the Adephaga, and possibly learn more about the ancestral AKH of beetles. Moreover, we wanted to compare the ancestral AKH with AKHs of more advanced beetles, of which a number are pest insects. This would allow us to assess whether AKH mimetics would be suitable as insecticides, that is, be harmful to the pest species but not to the beneficial species. Nine species of the Adephaga were investigated and all synthesize only one octapeptide in the corpus cardiacum, as revealed by Edman degradation sequencing techniques or by mass spectrometry. The amino acid sequence pGlu-Leu-Asn-Phe-Ser-Thr-Gly-Trp corresponds to Schgr-AKH-II that was first identified in the desert locust. It is assumed that Schgr-AKH-II-the peptide of a basal beetle clade-is the ancestral AKH for beetles. Some other beetle families, as well as some Hymenoptera (including honey bees) also contain this peptide, whereas most of the pest beetle species have different AKHs. This argues that those peptides and their receptors should be explored for developing mimetics with insecticidal properties. A scenario where Schgr-AKH-II (the only AKH of Adephaga) is used as basic molecular structure to derive almost all other known beetle AKHs via single step mutations is very likely, and supports the interpretation that Schgr-AKH-II is the ancestral AKH of Coleoptera.
[Mh] Termos MeSH primário: Coleópteros/genética
Evolução Molecular
Hormônios de Inseto/genética
Neuropeptídeos/genética
Ácido Pirrolidonocarboxílico/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Coleópteros/química
Coleópteros/metabolismo
Hormônios de Inseto/análise
Hormônios de Inseto/biossíntese
Hormônios de Inseto/química
Masculino
Neuropeptídeos/análise
Neuropeptídeos/biossíntese
Neuropeptídeos/química
Periplaneta
Ácido Pirrolidonocarboxílico/análise
Ácido Pirrolidonocarboxílico/química
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insect Hormones); 0 (Neuropeptides); 134599-16-9 (adipokinetic hormone, beetle); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170617
[St] Status:MEDLINE
[do] DOI:10.1002/arch.21399


  7 / 2693 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28511162
[Au] Autor:Babinets LS; Kytsai KY; Kotsaba YY; Halabitska IM; Melnyk NA; Semenova IV; Zemlyak OS
[Ad] Endereço:Department Of Primary Health Care And General Practice/Family Medicine. Shei "Ternopil State Medical University By I. Horbachevsky Of Mph Of Ukraine", Ternopil, Ukraine.
[Ti] Título:Improvement of the complex medical treatment for the patients wÑ–th chronic biliary pancreatitis.
[So] Source:Wiad Lek;70(2):213-216, 2017.
[Is] ISSN:0043-5147
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The most common reason of chronic pancreatitis is liver and bile ducts disease: functional disorders, chronic cholecystitis, cholelithiasis and cholecystectomy in medical history. All these changes are associated with the colloidal structure of bile, increased lithogenicity, gallstones formation, Oddi's sphincter dysfunction, dysmotility and inflammation in the bile ducts. THE AIM: to study the effectiveness of using medicine Liveria IC (metadoxine) in standard therapy as well as effect on spectrum of blood serum lipids and structural condition of liver (stiffness) and pancreas in patients with chronic biliary pancreatitis combined with obesity. MATERIALS AND METHOD: 115 patients suffering from chronic biliary pancreatitis and obesity were the subjects of the study. They were compared to etiological factor socioeconomic conditions and nutrition (regular food 5 times a day without aggressive food (fatty, spicy, sour, fried products)). Also the effect of the alcohol factor was excluded. RESULTS: The obtained decrease in stiffness of the liver and pancreas indicates an improvement of their structural state. CONCLUSIONS: Using medication LiveriaIC (metadoxine) as the part of the complex therapy for the patients who are suffering from CBP combined with obesity gives some improvement of the lipid profile indices and the structural condition of liver and pancreas (according to the data of SWE) (Ñ€<0.05).
[Mh] Termos MeSH primário: Fígado/efeitos dos fármacos
Pâncreas/efeitos dos fármacos
Pancreatite Crônica/tratamento farmacológico
Piridoxina/uso terapêutico
Ácido Pirrolidonocarboxílico/uso terapêutico
[Mh] Termos MeSH secundário: Colecistectomia/efeitos adversos
Colecistite/complicações
Colelitíase/complicações
Combinação de Medicamentos
Feminino
Seres Humanos
Fígado/patologia
Masculino
Meia-Idade
Obesidade/complicações
Pâncreas/patologia
Pancreatite Crônica/etiologia
Pancreatite Crônica/patologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); EJQ7M98H5J (metadoxine); KV2JZ1BI6Z (Pyridoxine); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170707
[Lr] Data última revisão:
170707
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170517
[St] Status:MEDLINE


  8 / 2693 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28490097
[Au] Autor:Wegener S; Kaufmann M; Kroh LW
[Ad] Endereço:Institute of Food Technology and Food Chemistry, Technical University of Berlin, Gustav-Meyer-Allee 25, 13355 Berlin, Germany. Electronic address: steffen.wegener@mailbox.tu-berlin.de.
[Ti] Título:Influence of l-pyroglutamic acid on the color formation process of non-enzymatic browning reactions.
[So] Source:Food Chem;232:450-454, 2017 Oct 01.
[Is] ISSN:0308-8146
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Heating aqueous d-glucose model reactions with l-glutamine and l-alanine yielded similar colored solutions. However, size-exclusion chromatography (SEC) revealed that both non-enzymatic browning reactions proceeded differently. Due to a fast occurring cyclization of l-glutamine to pyroglutamic acid, the typical amino-carbonyl reaction was slowed down. However, l-glutamine and l-alanine model reactions showed the same browning index. Closer investigations could prove that l-pyroglutamic acid was able to influence non-enzymatic browning reactions. SEC analyses of d-glucose model reactions with and without l-pyroglutamic acid revealed an increase of low molecular colored compounds in the presence of l-pyroglutamic acid. Polarimetric measurements showed a doubling of d-glucose mutarotation velocity and HPLC analyses of d-fructose formation during thermal treatment indicated a tripling of aldose-ketose transformation in the presence of l-pyroglutamic acid, which are signs of a faster proceeding non-enzymatic browning process. 2-Pyrrolidone showed no such behavior, thus the additional carboxylic group should be responsible for the observed effects.
[Mh] Termos MeSH primário: Reação de Maillard
Ácido Pirrolidonocarboxílico
[Mh] Termos MeSH secundário: Alanina
Glucose
Glutamina
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0RH81L854J (Glutamine); IY9XDZ35W2 (Glucose); OF5P57N2ZX (Alanine); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170901
[Lr] Data última revisão:
170901
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170512
[St] Status:MEDLINE


  9 / 2693 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28440594
[Au] Autor:Park Y; Kim Y
[Ad] Endereço:Department of Bio-Sciences, Andong National University, Andong, Korea.
[Ti] Título:Identification of a hypertrehalosemic factor in Spodoptera exigua.
[So] Source:Arch Insect Biochem Physiol;95(1), 2017 May.
[Is] ISSN:1520-6327
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Trehalose is a major blood sugar in insects with a range of physiological functions, including an energy source and a cryoprotectant. Hemolymph trehalose concentrations are tightly regulated according to physiological conditions. An insulin-like peptide, SeILP1, downregulates hemolymph trehalose concentrations in Spodoptera exigua. Here, we identified a factor that upregulates hemolymph trehalose concentration in S. exigua. Hemolymph trehalose concentrations were significantly increased after immune challenge or under starvation in a time-dependent manner. To determine endocrine factors responsible for the upregulation, stress-associated mediators, such as octopamine, serotonin, or eicosanoids were injected, but they did not upregulate hemolymph trehalose. On the other hand, injection with Schistocerca gregaria adipokinetic hormone (AKH) significantly increased hemolymph trehalose concentration in S. exigua. During upregulation of hemolymph trehalose by AKH injection, trehalose degradation appeared to be inhibited because expression of trehalase and SeILP1 were significantly suppressed while that of trehalose phosphate synthase was not significantly changed. Interrogation of a Spodoptera genome database identified an S. exigua AKH-like gene and its expression was confirmed. During starvation, its expression concentrations were increased, although RNA interference specific to the AKH-like hypertrehalosemic factor (SeHTF) gene significantly prevented the upregulation of hemolymph trehalose concentrations during starvation. A synthetic peptide of SeHTF was prepared and injected into S. exigua larvae. At nanomolar concentration, the synthetic SeHTF peptide effectively upregulated hemolymph trehalose concentrations. Here we report a novel hypertrehalosemic factor in S. exigua (SeHTF).
[Mh] Termos MeSH primário: Proteínas de Insetos/genética
Proteínas de Insetos/metabolismo
Spodoptera/metabolismo
Trealose/metabolismo
[Mh] Termos MeSH secundário: Animais
Regulação da Expressão Gênica/efeitos dos fármacos
Genoma de Inseto
Gafanhotos/química
Hemolinfa/metabolismo
Hormônios de Inseto/farmacologia
Proteínas de Insetos/farmacologia
Oligopeptídeos/farmacologia
Ácido Pirrolidonocarboxílico/análogos & derivados
Ácido Pirrolidonocarboxílico/farmacologia
Interferência de RNA
Spodoptera/efeitos dos fármacos
Spodoptera/genética
Inanição
Trealase/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insect Hormones); 0 (Insect Proteins); 0 (Oligopeptides); 0 (adipokinetic hormone); B8WCK70T7I (Trehalose); EC 3.2.1.28 (Trehalase); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170720
[Lr] Data última revisão:
170720
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170426
[St] Status:MEDLINE
[do] DOI:10.1002/arch.21386


  10 / 2693 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28409830
[Au] Autor:Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
[Ad] Endereço:Department of Community Medicine, Melaka-Manipal Medical College, Jalan Batu Hampar, Bukit Baru, Melaka, Malaysia, 75150.
[Ti] Título:Magnesium for treating sickle cell disease.
[So] Source:Cochrane Database Syst Rev;4:CD011358, 2017 Apr 14.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Sickle cell disease is an autosomal recessive inherited haemoglobinopathy which causes painful vaso-occlusive crises due to sickle red blood cell dehydration. Vaso-occlusive crises are common painful events responsible for a variety of clinical complications; overall mortality is increased and life expectancy decreased compared to the general population. Experimental studies suggest that intravenous magnesium has proven to be well-tolerated in individuals hospitalised for the immediate relief of acute (sudden onset) painful crisis and has the potential to decrease the length of hospital stay. Some in vitro studies and open studies of long-term oral magnesium showed promising effect on pain relief but failed to show its efficacy. The studies show that oral magnesium therapy may prevent sickle red blood cell dehydration and prevent recurrent painful episodes. There is a need to access evidence for the impact of oral and intravenous magnesium effect on frequency of pain, length of hospital stay and quality of life. OBJECTIVES: To evaluate the effects of short-term intravenous magnesium on the length of hospital stay and quality of life in children and adults with sickle cell disease. To determine the effects of long-term oral magnesium therapy on the frequency of painful crises and the quality of life in children and adults with sickle cell disease. SEARCH METHODS: We searched the Cochrane Haemoglobinopathies Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books.Date of last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 01 December 2016.Date of last search of other resources (clinical trials registries): 29 March 2017. SELECTION CRITERIA: We searched for published and unpublished randomized controlled studies of oral or intravenous magnesium compared to placebo or no magnesium. DATA COLLECTION AND ANALYSIS: Authors independently assessed the study quality and extracted the data using standard Cochrane methodologies. MAIN RESULTS: We included five randomized placebo-controlled studies with a total of 386 participants (aged three to 53 years). Two shorter parallel studies (n = 306) compared intravenous magnesium sulphate to placebo (normal saline) for admission to hospital due to a vaso-occlusive crisis, for which we were able to analyse data. The quality of evidence was moderate for studies presenting this comparison mainly due to limitations due to risk of bias and imprecision. Two of the three longer-term studies comparing oral magnesium pidolate to placebo had a cross-over design. The third was a parallel factorial study which compared hydroxyurea and oral magnesium to each other and to placebo over a longer period of time; we only present the comparison of oral magnesium to placebo from this study. The quality of evidence was very low with uncertainty of the estimation.The eight-hourly dose levels in the two studies of intravenous magnesium were different; one used 100 mg/kg while the second used 40 mg/kg. Only one of these studies (n = 104) reported the mean daily pain score while hospitalised (a non-significant difference between groups, moderate quality evidence). The second study (n = 202) reported a number of child- and parent-reported quality of life scores. None of the scores showed any difference between treatment groups (low quality evidence). Data from one study (n = 106) showed no difference in length of stay in hospital between groups (low quality evidence). Both studies reported on adverse events, but not defined by severity as we had planned. One study showed significantly more participants receiving intravenous magnesium experienced warmth at infusion site compared to placebo; there were no differences between groups for other adverse events (low quality evidence).Three studies (n = 80) compared oral magnesium pidolate to placebo. None of them reported data which we were able to analyse. One study (n = 24) reported on the number of painful days and stated there was no difference between two groups (low quality evidence). None of the studies reported on quality of life or length of hospital stay. Two studies (n = 68) reported there were no differences in levels of magnesium in either plasma or red blood cells (moderate quality evidence). Two studies (n = 56) reported adverse events. One reported episodes of mild diarrhoea and headache, all of which resolved without stopping treatment. The second study reported adverse events as gastrointestinal disorders, headache or migraine, upper respiratory infections and rash; which were all evenly distributed across treatment groups (moderate quality evidence). AUTHORS' CONCLUSIONS: Moderate to low quality evidence showed neither intravenous magnesium and oral magnesium therapy has an effect on reducing painful crisis, length of hospital stay and changing quality of life in treating sickle cell disease. Therefore, no definitive conclusions can be made regarding its clinical benefit. Further randomized controlled studies, perhaps multicentre, are necessary to establish whether intravenous and oral magnesium therapies have any effect on improving the health of people with sickle cell disease.
[Mh] Termos MeSH primário: Anemia Falciforme/tratamento farmacológico
Antidrepanocíticos/uso terapêutico
Magnésio/uso terapêutico
[Mh] Termos MeSH secundário: Administração Oral
Adolescente
Adulto
Anemia Falciforme/sangue
Criança
Pré-Escolar
Seres Humanos
Hidroxiureia/uso terapêutico
Injeções Intravenosas
Magnésio/efeitos adversos
Magnésio/sangue
Sulfato de Magnésio/uso terapêutico
Meia-Idade
Medição da Dor
Pais
Ácido Pirrolidonocarboxílico/uso terapêutico
Qualidade de Vida
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antisickling Agents); 7487-88-9 (Magnesium Sulfate); I38ZP9992A (Magnesium); SZB83O1W42 (Pyrrolidonecarboxylic Acid); X6Q56QN5QC (Hydroxyurea)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170801
[Lr] Data última revisão:
170801
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170415
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD011358.pub2



página 1 de 270 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde